Related Experiment Videos
Asthma--new drugs on the horizon?
1Department of Medicine, National University of Singapore.
Annals of the Academy of Medicine, Singapore
|November 1, 1993
Summary
Recent asthma drug development has yielded many new treatments. However, few novel asthma therapies demonstrate significant clinical benefits, necessitating careful evaluation of their efficacy in patients.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Medicine
Background:
- Significant advancements in understanding asthma pathophysiology have occurred over the past decade.
- Numerous new drugs for asthma treatment have been developed concurrently.
- Many promising asthma medications have ultimately shown limited clinical benefits.
Purpose of the Study:
- To review recent developments in asthma drug classes.
- To focus on the clinical efficacy of these new and established asthma treatments.
- To provide an overview of novel and updated therapeutic agents for asthma management.
Main Methods:
- Literature review of recent pharmacological developments in asthma.
- Analysis of clinical trial data for various asthma drug classes.
- Evaluation of the therapeutic relevance of new drugs for asthmatic patients.
Main Results:
- Novel drug classes, including ion channel blockers and receptor antagonists (thromboxane, leukotriene, platelet activating factor), have emerged.
- Updates on established asthma medications, such as long-acting beta 2-adrenergic receptor agonists, are discussed.
- Immunoregulatory drugs represent another area of development for asthma treatment.
Conclusions:
- Despite extensive research, few novel asthma drugs have proven substantial clinical benefits.
- Careful clinical evaluation is crucial for determining the real-world effectiveness of new asthma therapies.
- The review emphasizes the importance of evidence-based selection of asthma medications for patient care.